BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrackMyForm//trackmyform.in//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrackMyForm deadlines
BEGIN:VEVENT
UID:aiimsj-efficacy-and-safety-of-substitution-of-bleomycin-by-low-dose-niv
 olumba-in-closes@trackmyform.in
SEQUENCE:0
LAST-MODIFIED:20260908T025747Z
DTSTAMP:20260908T025747Z
DTSTART;VALUE=DATE:20260910
DTEND;VALUE=DATE:20260911
SUMMARY:Last date — AIIMS Jodhpur Efficacy and safety of substitution of 
 bleomycin by low dose nivolumba in ABVD (Doxorubicin + Bleomycin + Vinblas
 tine + Dacarbazine) backbone chemotherapy in newly diagnosed advanced-stag
 e pediatric Hodgkin Lymphoma: A phase II/III\, multicentric\, open-label\,
  randomized controlled trial 2026
DESCRIPTION:Last date to apply. AIIMS Jodhpur Efficacy and safety of substi
 tution of bleomycin by low dose nivolumba in ABVD (Doxorubicin + Bleomycin
  + Vinblastine + Dacarbazine) backbone chemotherapy in newly diagnosed adv
 anced-stage pediatric Hodgkin Lymphoma: A phase II/III\, multicentric\, op
 en-label\, randomized controlled trial 2026. Every date on this page was r
 ead from the recruiter's own notification — check it against the officia
 l document before you rely on it.
URL:https://trackmyform.in/aiimsj-efficacy-and-safety-of-substitution-of-bl
 eomycin-by-low-dose-nivolumba-in/
TRANSP:TRANSPARENT
BEGIN:VALARM
ACTION:DISPLAY
TRIGGER:-P7D
DESCRIPTION:A week left — AIIMS Jodhpur Efficacy and safety of substituti
 on of bleomycin by low dose nivolumba in ABVD (Doxorubicin + Bleomycin + V
 inblastine + Dacarbazine) backbone chemotherapy in newly diagnosed advance
 d-stage pediatric Hodgkin Lymphoma: A phase II/III\, multicentric\, open-l
 abel\, randomized controlled trial 2026
END:VALARM
BEGIN:VALARM
ACTION:DISPLAY
TRIGGER:-PT9H
DESCRIPTION:Closes today — AIIMS Jodhpur Efficacy and safety of substitut
 ion of bleomycin by low dose nivolumba in ABVD (Doxorubicin + Bleomycin + 
 Vinblastine + Dacarbazine) backbone chemotherapy in newly diagnosed advanc
 ed-stage pediatric Hodgkin Lymphoma: A phase II/III\, multicentric\, open-
 label\, randomized controlled trial 2026
END:VALARM
END:VEVENT
END:VCALENDAR